Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
571.25 M
About U.S. Stem Cell, Inc.
Sector
Industry
CEO
Miguel Tomás
Website
Headquarters
Sunrise
Founded
1999
FIGI
BBG000R0ZT52
U.S. Stem Cell, Inc. is a biotechnology company, which engages in the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product, MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.
USRM Just broke the 30sma! Setting up for a pop?USRM 5-8 .0990 Watch for the break of .1030 Setting up here for a move imo after the 30sma break. Res .1030/.12 Support .0867/.07
$USRM From .0045 Onwards She is Ready for the 4th Leg UpBy far one of my top 3 favorite stocks so far this year, our Bio baby has proven her stamina. She has hit the .08 support at triple bottom and is ready for a 4th massive move upwards. With Institutional investors now throwing upwards of $5 million in financing at her for a stake in what is to be a p
$USRM Alerted from .012 Currently on 3rd Major Breakout Setup$USRM is currently awaiting RMAT designation which approved (And there is a 90% or higher chance it will) gives it similar qualities as Breakthrough Therapy, Accelerated Approval, and Priority Review. Basically, they can provisionally approve the drug or device for marketing and then provided the dr
$USRM Absolutely beautiful day todayThree Key Factors happened today on $USRM
1. We had a Cloud break for the first time in a while
2. Volume Increased
3. Resistance became Support
4. Ultimate support held
5. Bullish trend continues
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of USRM is 0.000100 USD — it hasn't changed in the past 24 hours. Watch U.S. Stem Cell, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange U.S. Stem Cell, Inc. stocks are traded under the ticker USRM.
USRM reached its all-time high on Feb 19, 2008 with the price of 5,250.000000 USD, and its all-time low was 0.000001 USD and was reached on Sep 18, 2023. View more price dynamics on USRM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
USRM stock is 0.00% volatile and has beta coefficient of −33.42. Track U.S. Stem Cell, Inc. stock price on the chart and check out the list of the most volatile stocks — is U.S. Stem Cell, Inc. there?
Yes, you can track U.S. Stem Cell, Inc. financials in yearly and quarterly reports right on TradingView.
U.S. Stem Cell, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
No, USRM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, USRM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade U.S. Stem Cell, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So U.S. Stem Cell, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating U.S. Stem Cell, Inc. stock shows the sell signal. See more of U.S. Stem Cell, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.